keine Finanzberatung

PFE · Pfizer Inc.

Global pharma giant, post-Covid reset

Risiko 5/10 · MODERATE RISK · patent-cliff pharma · $28.45 ▼ 1.25%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $28.45
  • Market cap $162.2B
  • P/E (ttm) 37.43
  • Div yield 6.05%
  • 52-wk range $23.58 – $29.21
  • Index rank #88 / —

Wichtigste Risiken

  • Patent cliff hits key drugs late this decade (Shareholders) — HIGH
  • Pipeline fails to refill lost revenue (Shareholders) — HIGH
  • US drug-pricing policy squeezes margins (Shareholders) — MED
  • Dividend strains if earnings slip further (Shareholders) — MED

Fazit

A bond-like yield with a pharma lottery ticket attached — fine for income, but the pipeline must outrun the cliff.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.